CAJ | 학술논문

目的：观察紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的临床疗效和毒副作用。方法选择该院收治的晚期非小细胞肺癌患者80例分为研究组和对照组，各40例。研究组给予紫杉醇脂质体（135mg/m2，静脉滴注3h，第1天），对照组给予紫杉醇（135mg/m2，静脉滴注3h，第1天），两组均联合使用顺铂75mg/m2，静脉滴注，分3d给予，以21d为1个周期。评价两组近期疗效、远期疗效和毒副反应。结果研究组与对照组总有效率（RR）分别为27．5％、25．0％，二者比较差异无统计学意义（P＞0．05）。研究组皮疹、肌肉/关节酸痛、周围神经病变发生率显著低于对照组（P＜0．05）。研究组无进展生存期为5．3个月（95％CI3．713～6．408），中位生存期为9．3个月（95％CI8．337～9．907）；对照组无进展生存期为4．6个月（95％CI3．187～5．547），中位生存期为9．4个月（95％CI7．787～11．602），两组比较差异无统计学意义（P＞0．05）。结论紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌临床近期疗效及远期疗效与紫杉醇相当，但其过敏反应较低。
목적：관찰자삼순지질체연합순박치료만기비소세포폐암적림상료효화독부작용。방법선택해원수치적만기비소세포폐암환자80례분위연구조화대조조，각40례。연구조급여자삼순지질체（135mg/m2，정맥적주3h，제1천），대조조급여자삼순（135mg/m2，정맥적주3h，제1천），량조균연합사용순박75mg/m2，정맥적주，분3d급여，이21d위1개주기。평개량조근기료효、원기료효화독부반응。결과연구조여대조조총유효솔（RR）분별위27．5％、25．0％，이자비교차이무통계학의의（P＞0．05）。연구조피진、기육/관절산통、주위신경병변발생솔현저저우대조조（P＜0．05）。연구조무진전생존기위5．3개월（95％CI3．713～6．408），중위생존기위9．3개월（95％CI8．337～9．907）；대조조무진전생존기위4．6개월（95％CI3．187～5．547），중위생존기위9．4개월（95％CI7．787～11．602），량조비교차이무통계학의의（P＞0．05）。결론자삼순지질체연합순박치료만기비소세포폐암림상근기료효급원기료효여자삼순상당，단기과민반응교저。
Objective To observe the effects and toxicity of paclitaxel liposome combined with cisplatin in the treatment of ad-vanced non-small cell lung cancer .Methods 80 cases of patients of advanced non-small cell lung cancer were randomly divided into study group and control group ,40 cases in each group .Study group was treated with paclitaxel liposome (135 mg/m2 ,IV drip 3 h , first days) ,control group received paclitaxel(135 mg/m2 ,IV drip 3 h ,first days) ,the two groups combined with cisplatin 75 mg/m2 ,IV drip ,for 3 days ,take 21 days as one cycle .Results The study group CR 0 .0% (0/40) ,PR 27 .5% (11/40) ,RR 27 .5% (11/40);control group CR 0 .0% (0/40) ,PR 25 .0% (10/40) ,PR 25 .0% (10/40) ,(P>0 .05) .The research group of rash ,muscle and joint pain ,peripheral neuropathy was significantly lower than that of the control group (P<0 .05) .The research group of progres-sion-free survival was 5 .3 months(95% CI 3 .713 -6 .408) ,the median survival period was 9 .3 months(95% CI 8 .337 -9 .907);control group of progression-free survival was 4 .6 months(95% CI 3 .187 -5 .547) ,the median survival period was 9 .4 months (95% CI 7 .787-11 .602) ,the two groups had no statistical significance (P>0 .05) .Conclusion Paclitaxel liposome combined with cisplatin in treatment of advanced non-small cell lung cancer clinical efficacy and long-term efficacy of taxol and quite ,but with less allergic reaction .